How It Works
MSCs can be extracted from adult fat and bone marrow, as well as peripheral blood, 8, 9 and can be induced to differentiate into various mesenchymal tissues including bone, cartilage, and muscle. 10, 11 In vitro induction can be accomplished by growth factor supplementation and creating culturing conditions that are favorable for the preferred differentiation. Specifically, adipogenic differentiation from MSCs has been successfully accomplished in Dulbecco's modified Eagle medium supplemented with isobutylmethylxanthine, indomethacin, and either dexamethasone and insulin or with hydrocortisone. 11, 12 Successful induction is then verified by the identification of lipid vacuoles within the cell and various other adipose cell markers. In comparison, in vitro chondrogenic differentiation has been induced by centrifuging the MSCs into micromass pellets and culturing in a medium containing dexamethasone and transforming growth factor β-3. 13 Chrondrocytes are then detected by the presence of secreted extracellular matrix components such as type II collagen and aggrecan, among others.
14 Osteogenic differentiation may be induced in a culture of dexamethasone, ascorbic acid phosphate, β-glycerol phosphate; 11, 12, 14, 15 successful differentiation is identified by the expression of alkaline phosphate and using cell-specific antibodies. Successful models used to expand the MSC population and induce osteogenic differentiation have also included substances such as transforming growth factor-β and fibroblast growth factor-2. 16, 17 Bone morphogenetic protein has also been shown to successfully expand the osteogenic cell population; 7,18 however, limitations exist regarding cost and safety. The authors refer the interested reader to some of the early studies inducing MSC differentiation for additional explanations as to the nature and function of the specific growth factor supplements. [11] [12] [13] [14] [19] [20] [21] In vivo induction occurs through site-specific differentiation and is often implanted within scaffolds.
7,10
In addition to requiring sufficient numbers of MSCs implanted for bone regeneration, 22 an osteoconductive matrix is also necessary for osseous growth. 18 The scaffold provides a structural support for cell-cell interactions, extracellular matrix formation, and new tissue formation. The osteoconductive scaffold occupies the site of the fusion, but also provides an environment conducive for the osteoinductive factors and tissue growth. Various biomaterials have been investigated as scaffolds including hydroxyapatite, tricalcium phosphate, calcium sulfate, metals, and biodegradable polymers. 23 Serving as the initial structure for tissue growth and blood vessel formation, the biodegradable types of scaffolds eventually resorb as new bone is formed.
24
Isolating human MSCs has traditionally been accomplished by using their selective adherence to plastic surfaces, which the hematopoietic cells less commonly do. 25 This method, however, typically leads to heterogeneous cell isolation, in which only $30% of the cells are multipotent MSCs.
26
Although the MSCs do not express the cell surface markers normally found on hematopoietic cells, such as CD34 and CD45, there are cell markers that are unique to the MSCs.
27
Stro-1 was one of the earlier monoclonal antibodies developed to isolate MSCs, 28 and this was followed by additional cell-surface markers such as CD146, CD200, and CD271.
29-31
Use of these markers alone may not be sufficient to isolate pure samples of MSCs. Gronthos and colleagues 28 described a method whereby they used Stro-1 monoclonal antibodies and then isolated the cells using immunomagnetic cell sorting (MACS). This resulted in a milieu of cells with varying intensities of STRO-1 fluorescence intensity, which was then further purified for the high-intensity fluorescing cells using fluorescence-activated cell sorting (FACS 36, 37 and in fact, they tend to alter the cytokine profile to an anti-inflammatory state by decreasing tumor necrosis factor-α and interferongamma and increasing interleukin-10, interleukin-4, and regulatory T cells. 38 MSCs have even been used for their immunosuppressive actions in treating acute graft-versushost disease. 39 For these reasons, host-versus-graft disease, or graft rejection, does not appear to be a problem with MSC use in spine fusion. The use of MSC therapy in bone regeneration has been and is currently investigated both in animal models and in the clinical setting. This is being done through both local implantation of the stem cells and via gene therapy, as well as through autologous transfer of engineered extracted MSCs. 
Animal Models

Clinical Studies
The earliest clinical studies involving MSCs involved small case studies of autologous MSCs used for bone regeneration. 58 weaker mechanical stability of the implanted graft and poor resorption of the bioceramic constructs, 74 and ambiguity surrounding the optimal cell concentration and delivery method. More studies examining optimal MSC concentrations are needed in larger animals, which are more comparable to humans, considering the fact that there is decreased potential for bone growth as compared with smaller animals (e.g., rabbits, rats, etc.). 58, 83, 84 This also demonstrates the need for methods to maximize the number of MSCs collected, as well as techniques that can be feasible in the operating room setting.
85
Other options can include obtaining somatic cells and converting them into pluripotent cells, 86 using minimally invasive approaches to collect and culture bone marrow-or adiposederived MSCs prior to surgery, and potentially even using recombinant forms of MSCs. The present hurdles to clinical use include optimization of osteoinductive and osteoconductive properties of MSCs in bone grafts. Vascularization of the implant and integration of the vasculature with the host will prove to be important; additionally the long-term mechanical strength and durability, particularly at the load-bearing sites such as the lower lumbar spine regions will need to be comparable to native bone.
87
Conclusion
Allogeneic MSC therapy for spine fusion and other skeletal treatments is still in its infancy. There has been a surge of interest in the various MSC formulations commercially available for clinical use in spinal surgery. This enthusiasm, and clinical use, must be tempered with the understanding that there are no clinical data that had defined the efficacy or safety profiles in spine surgery patients. Therefore, it is imperative that the spine surgery community carefully evaluate the use of MSC in spine fusion through well-designed and executed studies. Although more than a decade of preclinical animal research that has shown promising results, the safety and efficacy of these products in randomized controlled trials must be ascertained. With the rapidly growing number of spine fusion surgeries performed annually, further study into fusion-enhancing compounds becomes increasingly necessary. MSC therapy remains an interesting and important avenue of research.
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